Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
specific biomarker
|
| gptkbp:clinicalTrials |
gptkb:Canada
gptkb:United_States Europe Phase 3 followed by healthcare professionals |
| gptkbp:collaborations |
academic institutions
research organizations healthcare_providers |
| gptkbp:contraindication |
required_by_FDA
|
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:dosageForm |
injection
varies by indication |
| gptkbp:formulation |
liquid
|
| gptkbp:hasCompetitors |
biomarker tests
other diagnostic products other therapeutic products |
| gptkbp:healthcare |
provided by manufacturers
provided by healthcare providers |
| gptkbp:historicalResearch |
ongoing studies
improvements in formulation potential new indications |
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 2200
|
| gptkbp:label |
FDA_guidelines
|
| gptkbp:mandates |
specific disease or condition
|
| gptkbp:manufacturer |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:market |
2020
|
| gptkbp:marketedAs |
brand name
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
submitted_to_FDA
submitted_to_EMA submitted_to_Health_Canada |
| gptkbp:researchFocus |
biomarkers
diagnostic tests therapeutic applications |
| gptkbp:researchInterest |
available in clinical trial registries
available in medical journals available in pharmaceutical databases |
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
dizziness
fatigue headache nausea allergic reactions |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:supplyChain |
monitored for quality
available through clinics available through hospitals distributed through pharmacies regulated_by_FDA |
| gptkbp:targets |
children
adults |
| gptkbp:usedFor |
diagnosis of certain medical conditions
|